MT-MMP-6 Inhibitors

Chemical inhibitors of MT-MMP 6 offer a variety of mechanisms by which they can impede the protein's function. Marimastat, for example, binds to the catalytic domain of MT-MMP 6, which obstructs the protein's ability to interact with extracellular matrix components, thus stalling its proteolytic activity. Similarly, Ilomastat and GM6001 both act by chelating the zinc ion at the active site of MT-MMP 6; this is essential for the enzyme's activity, and its sequestration results in direct inhibition of the protein's function. In the case of Batimastat, the chemical is designed to occupy the active site of MT-MMP 6, thereby blocking substrate binding and subsequent degradation of the extracellular matrix. Prinomastat also serves as a structural mimic of MT-MMP 6 substrates, binding to the active site and thus inhibiting proteolytic activity. Furthermore, BMS-275291 operates by selectively binding to the catalytic domain of MT-MMP 6, thereby preventing it from engaging in the degradation of extracellular matrix proteins. SB-3CT targets a gelatinase-specific domain of MT-MMP 6 related to substrate recognition, which is crucial for the protein's ability to modify the extracellular environment. RO-28-2653 and PD166793 both function by competitively binding to the catalytic domain of MT-MMP 6, which reduces its proteolytic function. ONO-4817 inhibits MT-MMP 6 by blocking its catalytic zinc-binding domain, which is vital for the breakdown of extracellular matrix materials. Andecaliximab, while being a monoclonal antibody, acts by binding to the extracellular domain of MT-MMP 6, which inhibits the protein's activity at the cell surface level and its interaction with extracellular matrix proteins. Each of these chemicals targets specific domains or activities of MT-MMP 6, resulting in the inhibition of its ability to modulate its surrounding extracellular environment.